Ekso Bionics (EKSO) Investor presentation summary

Company overview and mission

• Focuses on advanced robotics to enhance, amplify, and restore human function, improving health and quality of life.

• Deep expertise in human-machine interface, with origins in DARPA-funded research and a strong medtech presence since 2008.

• Recognized for leadership in neuro-rehabilitation and robotic therapy, with over 1,000 devices deployed in 500+ centers globally.

Product portfolio and innovation

• Offers wearable robotics for enterprise health (neuro-rehabilitation in hospitals, VA centers) and personal health (home/community use).

• Devices FDA-cleared for spinal cord injury, stroke, traumatic brain injury, and multiple sclerosis; future indications include Parkinson's, ALS, and orthopedic recovery.

• Indego exoskeleton features fastest walking speeds, modular design, and wireless operation; user benefits include improved mobility, pain, and mental health.

• Developing AI-powered features, including a voice agent and leveraging a large motion data repository, through the NVIDIA Connect Program.

Market opportunity and growth strategy

• Addressable U.S. market estimated at $1B for post-acute, $1.9B for outpatient, and $13.2B for home use.

• CMS reimbursement for Indego Personal ($91K per device) effective April 2024, with first claims approved and a growing pipeline.

• Strategic partnerships with PRIA Healthcare, National Seating & Mobility, and Bionic P&O to scale distribution and market access.

• Go-to-market strategy leverages clinical relationships, physician prescriptions, and third-party providers for efficient reimbursement and training.